💊 GLP-1 Drugs
GLP-1 Drugs — Complete Guide to Ozempic, Wegovy, Mounjaro (2026)
Complete guide to GLP-1 receptor agonist medications. How they work, all available drugs, who qualifies, and the latest evidence. Updated January 2026.
Key Takeaways
- GLP-1 drugs now include 7 approved medications — from daily injections to weekly and oral forms
- Tirzepatide (Mounjaro) produces more weight loss than any other approved medication
- These drugs reduce cardiovascular events by 20–26% in people with existing heart disease
- All GLP-1 drugs cause weight regain when stopped — long-term or permanent treatment needed
- Oral semaglutide (Rybelsus) provides a tablet alternative to injections for T2 diabetes
What Are GLP-1 Drugs?
GLP-1 receptor agonists (GLP-1 RAs) are medications that mimic glucagon-like peptide-1 — a gut hormone released after eating. They activate GLP-1 receptors throughout the body, producing: reduced appetite, slower gastric emptying, improved insulin secretion (glucose-dependent), reduced glucagon release, and weight loss.
7
GLP-1 drugs currently approved (USA/UK)
26%
Cardiovascular event reduction with liraglutide (LEADER trial)
22%
Maximum average weight loss — tirzepatide 15mg (SURMOUNT-1)
All Approved GLP-1 Drugs Compared
| Drug (Brand) | Frequency | Weight Loss | Approved For | Notes |
|---|---|---|---|---|
| Semaglutide — Ozempic | Weekly injection | 9–14% | T2D + CVD | Most prescribed worldwide |
| Semaglutide — Wegovy | Weekly injection | 15–17% | Obesity | Higher dose than Ozempic |
| Semaglutide — Rybelsus | Daily oral tablet | 3–5% | T2D | Only oral GLP-1 |
| Tirzepatide — Mounjaro | Weekly injection | 15–22% | T2D + Obesity | Dual GLP-1/GIP agonist |
| Liraglutide — Victoza | Daily injection | 5–8% | T2D | Older, being phased out |
| Liraglutide — Saxenda | Daily injection | 5–8% | Obesity | Less effective than weekly |
| Dulaglutide — Trulicity | Weekly injection | 3–5% | T2D | Strong CVD evidence |
Cardiovascular Benefits
A landmark discovery: beyond glucose and weight, GLP-1 drugs have direct cardiovascular protective effects independent of weight loss:
- LEADER trial (liraglutide): 13% reduction in cardiovascular events
- SUSTAIN-6 (semaglutide): 26% reduction in cardiovascular events
- SELECT trial (semaglutide, non-diabetics): 20% CVD reduction — first major drug approved for CVD without diabetes
- REWIND (dulaglutide): 12% CVD reduction
Emerging GLP-1 Drugs (2026)
- Oral tirzepatide: Phase 3 trials showing impressive results — once-daily tablet equivalent to injection
- Retatrutide: Triple agonist (GLP-1 + GIP + glucagon) — early trials showing up to 24% weight loss
- CagriSema: Combined cagrilintide + semaglutide — 25% weight loss in early trials
🔢 Free Tool
Diabetes Risk Calculator
Get personalised results based on your own data.
Open Free Calculator →Frequently Asked Questions
Which GLP-1 drug is best for weight loss?▼
Tirzepatide (Mounjaro/Zepbound) currently produces the most weight loss — average 20–22% at the 15mg dose in the SURMOUNT-1 trial. Among GLP-1-only drugs, semaglutide 2.4mg (Wegovy) produces the most weight loss at 15–17%. For Type 2 diabetes with cardiovascular disease, both semaglutide and dulaglutide have strong cardiovascular outcome trial data.
Can you take GLP-1 drugs long-term?▼
Yes — they are designed as long-term chronic disease treatments. Studies up to 5 years show continued efficacy and safety. The main concern for long-term use is: continued management of side effects, monitoring thyroid function (animal data showed thyroid C-cell tumours — not confirmed in humans), and the pharmacoeconomic question of lifetime medication cost.
Are GLP-1 drugs safe?▼
GLP-1 drugs have an excellent safety profile in clinical trials involving tens of thousands of participants. Most adverse effects are gastrointestinal (nausea, vomiting — usually temporary). Rare but important: acute pancreatitis (avoid if history of pancreatitis), diabetic retinopathy worsening with rapid HbA1c improvement, and potential thyroid C-cell concerns (avoid in MEN2 or medullary thyroid carcinoma history).
Related Health Guides
Article
Mounjaro vs Ozempic
Article
Ozempic Complete Guide
Article
Wegovy Weight Loss Guide
Calculator
Diabetes Risk
⚕️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting or changing any medication or treatment.
Dr
Dr. Priya Sharma, MD
WellCalc Medical Contributor
All articles reviewed by qualified healthcare professionals following NHS, AHA, and WHO guidelines.